### Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective
Of the recurring themes that tend to circulate in the drug development discourse,  China is a uniquely fascinating and polarizing...

by Jonathan Montagu

[Read more](/content/balancing-the-risks-and-rewards-of-drug-development-in-china-a-small-biotech-ceo-perspective/index.html)

### A CEO’s Perspective on Navigating Choppy Market Waters
I’m far from the first person to point out the prolonged market challenges that have depressed the biotech fundraising environment...

by Jonathan Montagu

[Read more](/content/a-ceos-perspective-on-navigating-choppy-market-waters/index.html)

### A New Wave of Therapeutic Innovation Through Targeting Transcription Factors
In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one...

by Jonathan Montagu

[Read more](/content/a-new-wave-of-therapeutic-innovation-through-targeting-transcription-factors/index.html)

### ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies?
HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but...

by Jonathan Montagu

[Read more](/content/esmo-reflections-glimmers-of-hope-with-the-next-wave-of-i-o-therapies/index.html)

### Has Spring Sprouted New Growth in Immuno-Oncology?
As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days...

by Jonathan Montagu

[Read more](/content/has-spring-sprouted-new-growth-in-immuno-oncology/index.html)

### Signaling Complexes: A Ripe Opportunity for Drug Development
Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used...

by Jonathan Montagu

[Read more](/content/signaling-complexes-a-ripe-opportunity-for-drug-development/index.html)

### How We Balance the What and How at HotSpot
At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in...

by Jonathan Montagu

[Read more](/content/how-we-balance-the-what-and-how-at-hotspot/index.html)

### Moving Our Core Values Beyond Table Stakes
Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a...

by Jonathan Montagu

[Read more](/content/moving-our-core-values-beyond-table-stakes/index.html)

### Build It and They Will Come – New Review Spotlights the Scientific Momentum Building for CBL-B Inhibition
The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...

by Jonathan Montagu

[Read more](/content/build-it-and-they-will-come-new-review-spotlights-the-scientific-momentum-building-for-cbl-b-inhibition/index.html)

### Reimagining I-O with Our First Investigational Drug and a New Approach to Clinical Discovery
HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor...

by Jonathan Montagu

[Read more](/content/reimagining-i-o-with-our-first-investigational-drug-and-a-new-approach-to-clinical-discovery/index.html)